Dr. Karl Kieburtz is Professor of Neurology and of Community and Preventive Medicine at the University of Rochester Medical Center in Rochester, New York. His primary clinical and research interests are in the treatment of neurodegenerative diseases affecting the basal ganglia, particularly Parkinson’s disease, Huntington’s disease, and HIV related neurologic disorders. He has been an active participant in the research activities of the Parkinson Study Group since 1989 and currently chairs the Executive Committee. He is the principal investigator for the NINDS sponsored trials of neuroprotective agents for PD. His publications and presentations have focused on experimental therapeutics and clinical research design strategies.
Disclosure:
Grant support received by Amarin, Boehringer-Ingelheim, Cephalon, Medivation and Neurosearch.
Consultant for Novartis, Merr, Abbott, Eisai, Antipodean, Biogen Idec, Ceregene, Vernalis, Prestwick, Schwarz and Schering-Plough.